WND launches new biomedical enterprise

The launch ceremony of WuXi XDC is held in the Wuxi National Hi-tech District on July 19. [Photo/wnd.gov.cn]

WuXi XDC, a joint venture established by WuXi Biologics, a global open-access biologics technology platform company, and WuXi STA, a subsidiary of WuXi AppTec, was launched in the Wuxi National Hi-tech District on July 19.

With a total investment of $200 million, WuXi XDC will focus on providing end-to-end CDMO services for bioconjugate drugs, including antibody-drug conjugate drugs.

More than 40 ADC drugs are in various stages of development on its R&D platform now, including 15 projects that have submitted investigational new drug (IND) applications and six projects that are in phase II/III clinical trials.

WuXi XDC is expected to gather advantages from other bases to consolidate the world's leading integrated technology platform for bioconjugates with the world's highest-standard quality system, aiming to promote the development of high-quality bio-conjugated drugs from its global partners, according to the company.

Cui Rongguo, director of WND, said that the district sees biomedicine as a strategic emerging industry and will be heavily supported during the 14th Five-Year Plan (2021-25) period.

Cui said he expected leading biomedicine enterprises to help introduce more related firms and projects to the district and help perfect the industrial chain in WND.